Resources: Point of Care Testing for Clozapine
https://www.ncbi.nlm.nih.gov/pubmed/22137859
Nielsen, J., Thode. D., Stengar, E., Andersen, K., Sondrup, U., Hansen, TN., Munk, AM., Lykkegaard, S., Gosvig, A., Petrov, I., Le Quach, P. (2012). Hematological clozapine monitoring with a point-of-care device: a randomized cross-over trial. National Centre for Biotechnological Information, 1-3.
This journal examines the effectiveness and efficiencies of point of care hematological monitoring for the treatment compliance of clozapine. In this journal you will find evidence that supports the implementation of point of care testing for appropriate clozapine treated patients.
2. Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708436/
Kalaria, S. K. (2019, August 20). Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes. Retrieved November 25, 2019, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708436/
This journal is a literature review that will summarize process and current availability of point of care testing devices for monitoring clozapine. It also discusses the implementation of point of care testing devices to determine individualized dosing in clinical trials.
3. How clozapine patients can be monitored safely and effectively
Dixon, M. (2014, June 2). How clozapine can be monitored safely and effectively. Retrieved November 25, 2019, from The Pharmaceutical Journal: https://www.pharmaceutical-journal.com/cpd-and-learning/learning-article/how-clozapine-patients-can-be-monitored-safely-and-effectively/11138788.article?firstPass=false
In this journal Dixon discusses the importance of ongoing hematological monitoring during treatment with clozapine. Through this journal you will understand the process a patient must go through to have clozapine initiated and what ongoing monitoring is required. Dixon also reviews the possible adverse effects of clozapine and the incidences of those adverse effects.
4. HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™
Cision. (2019, October 17). HLS Therapeutics announces Health Canada grants medical device license for White Blood Cell Point-of-Care Device to be marketed as CSAN® PRONTO™ . Retrieved November 25, 2019, from Cision: https://www.newswire.ca/news-releases/hls-therapeutics-announces-health-canada-grants-medical-device-license-for-white-blood-cell-point-of-care-device-to-be-marketed-as-csan-r-pronto-tm--899297239.html
This news release identifies a new hematological monitoring device, the "CSAN Pronto" which will allow potential patients to have blood monitoring done outside of a lab. This device will allow more patients to access the treatment and eliminate barriers to complying with required lab monitoring. This will increase the usability of the medication and allow for more efficient response to any abnormal lab findings. This monitoring device can be utilized in the patients' home or the clinicians office.